Published in TB and Outbreaks Week, May 13th, 1996
Is thiacetazone a necessary evil or an unethical alternative to more costly antituberculosis therapies' That thorny question continues to be debated by tuberculosis experts treating patients in poor, developing regions such as Kenya.
Researchers J. van Grokom and D.K. Kibuga of Nairobi, Kenya's National Leprosy Tuberculosis Program suggest that while greater education regarding the potentially life-threatening toxicity of thiacetazone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.